Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — AusBiotech Invest 2023
21 slides from Arovella Therapeutics's conference presentation, Oct 30, 2023
Slide 1: AusBiotech Invest Presentation (ASX Release)
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 30 October 2023 AUSBIOTECH INVEST PRESENTATION Highlights: • Arovella presents at AusBiotech Invest 2023 For personal use only MELBOURNE, AUSTRALIA 30 October 2023: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focuse
Slide 2: Glossary and forward-looking statements
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 Glossary: iNKT cell – invariant Natural Killer T cells; CAR – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; TCR – T cell receptors are a group of proteins found on immune cells that recognise fragment
Slide 3: AusBioInvest 2023
ASX:ALA For personal use only AusBioInvest 2023 ASX: ALA October 2023
Slide 4: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment 4. Whilst this presentation is based on information from sources which are advice. The presentation is not intended to be comprehensive or provide all considered reliable, no representation or warranty, expres
Slide 5: Arovella's strengths
Arovella’s strengths Off-the-Shelf iNKT Lead Product Addressing Key Strong For personal use only Cell Platform Advancing to Clinic Unmet Need Leadership Group Developing off-the-shelf iNKT ALA-101, potential treatment Our iNKT cell platform is Leadership team and Board cell therapies to target blood
Slide 6: Strong leadership
Strong leadership Leadership For personal use only Dr. Michael Baker Dr. Nicole van der Weerden Dr. Mini Bharathan Dr. Robson Dossa Dr. Simon Poon CEO & MANAGING DIRECTOR CHIEF OPERATING OFFICER SVP DEVELOPMENT & VP MANUFACTURING & QUALITY DIRECTOR PROJECT TRANSLATIONAL MEDICINE MANAGEMENT Board of
Slide 7: Cell Therapy has revolutionised blood cancer treatment
Cell Therapy has revolutionised blood cancer treatment CAR-T cells have demonstrated their curative potential in blood cancers For personal use only Approval 2022 Product Year Revenue Cure CAR-T cells have 2017 US$1160m3 demonstrated ability to cure haematological 2017 US$536m4 cancers 2021 US$388
Slide 8: Emily Whitehead - Celebrating Years of CAR T-Cell Therapy
For personal use only Emily Whitehead - Celebrating 10 Years of CAR T-Cell Therapy https://emilywhiteheadfoundation.org/10-years-of-car-t/ ASX:ALA 6
Slide 9: How original CAR-T cell therapies work
How original CAR-T cell therapies work CAR-T cell therapy is personalised medicine T cells = immune cell For personal use only T cells are a common type of immune cell that fight infections and can help fight cancer. T cells from patient ‘reprogrammed’ To generate autologous CAR-T cells, T cells are
Slide 10: CAR-T cell therapies pose challenges: supply chain costs
CAR-T cell therapies pose challenges Arovella’s off-the-shelf CAR-iNKT cell platform The current supply chain results in very high costs with potential for improved efficacy T cell For personal use only Manufacturing High drug pricing T cell & supply chain (>US$500k per costs are high patient) T cel
Slide 11: CAR-T cell therapies pose challenges: manufacturing time
CAR-T cell therapies pose challenges Arovella’s off-the-shelf CAR-iNKT cell platform The manufacturing time can block patient access with potential for improved efficacy For personal use only Patient may Time is an issue die waiting for for patients with treatment aggressive disease 4-6 weeks manufa
Slide 12: Introducing invariant Natural Killer T (iNKT) cells
Introducing invariant Natural Killer T (iNKT) cells Bridging the innate and adaptive immune system For personal use only Innate Immunity Adaptive Immunity ASX:ALA 10
Slide 13: iNKT cells represent a next-gen cell therapy
iNKT cells represent a next-gen cell therapy Properties make them ideal for use in cell therapy Front line of the human For personal use only immune system ▪ Innate Bridge innate & adaptive immune responses ▪ Contain both T cell & NK cell killing Immunity mechanisms ▪ Naturally target & kill cancers
Slide 14: A differentiated position
A differentiated position T cell and NK cell sectors are competitive For personal use only T cell iNKT cell NK cell Companies with T cell, NK cell, or iNKT cell therapy programs. Source: Company analysis based on public information ASX:ALA 12
Slide 15: Recent cell therapy transactions
Recent cell therapy transactions Upfront Milestones Total deal Date Type of deal Acquirer/Licensee Target/Licensor Cell Type Stage (US$M) (US$M) value (US$M) For personal use only Aug-23 License1 T Cell Phase 1b $21 $206 $227 Strategic Investment Aug-23 (ROFR) 2 T Cell Phase 1 $25 $0 $25 May-23 Lice
Slide 16: Financial overview
Financial overview Financial Snapshot ALA Price and Volume - 12 Months1 ASX CODE ALA For personal use only Market capitalisation1 $81.5 million 40,000,000 $0.10 Shares on issue 906.31 million $0.08 52-week low / high1 $0.020 / $0.105 30,000,000 Cash Balance (September 30 2023)2 $5.32 million $0.06 M
Slide 17: Arovella's expanding pipeline
Arovella’s expanding pipeline CD19-CAR CD19-CAR Novel Targets To target solid tumours For personal use only ALA-101 ALA-101 + onCARlytics CLDN18.2 and DKK1 Cytokine Technology Non-Hodgkin’s Head and Prostate Brain Triple negative Pancreatic Gastric Lung Cancer Lymphoma Neck Cancer Cancer Metastases
Slide 18: Milestones and news flow for FY2024
Milestones and news flow for FY2024 June December June 2023 2023 2024 For personal use only ▪ Complete process optimisation and scale-up in ▪ Complete cGMP manufacture for phase I clinical ALA-101 preparation for cGMP manufacture trials ▪ Complete production of cGMP lentiviral vector ▪ Complete prep
Slide 19: Summary
Summary Novel allogeneic Lead product progressing CAR-iNKT cell platform to clinical trials For personal use only iNKT cells serve as an excellent platform ALA-101, a potential treatment for to develop allogeneic, or “off-the-shelf”, CD19-expressing blood cancers, is cell therapies to treat cancer b
Slide 20: Thank You
ASX:ALA For personal use only Thank You Dr. Michael Baker CEO & Managing Director Email: investor@arovella.com Mobile: +61 403 468 187
Slide 21: Cell therapy deal references
Cell therapy deal references 1. https://www.businesswire.com/news/home/20230815091930/en/Precision-BioSciences-Completes-Strategic-Transaction-with- Imugene-for-Azer-Cel-in-Cancer 2. https://www.astellas.com/en/news/28271 3. https://www.jnj.com/janssen-enters-worldwide-collaboration-and-license-agre